证券代码：603387 证券简称：基蛋生物 公告编号：2026-003 基蛋生物科技股份有限公司 关于证券事务代表辞职的公告 王娇女士在担任公司证券事务代表期间恪尽职守、勤勉尽责，公司及董事会 对她在任职期间为公司发展所做出的贡献表示衷心感谢！ 特此公告。 基蛋生物科技股份有限公司董事会 2026 年 3 月 27 日 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 基蛋生物科技股份有限公司（以下简称"公司"）董事会近日收到证券事务 代表王娇女士递交的书面辞职报告。王娇女士因个人原因申请辞去公司证券事务 代表职务，辞职后不再担任公司任何职务。辞职报告自送达公司董事会之日起生 效。 截至本公告披露日，王娇女士未持有公司股份。其离任不会影响公司相关工 作的正常开展，所负责的工作已妥善交接至现有团队人员。 根据《上海证券交易所股票上市规则》等相关规定，公司董事会将于近期聘 任符合任职资格的人员担任证券事务代表职务。 ...

Market Overview - A-shares opened lower but rose throughout the day, with major indices collectively increasing and turning positive [1] - The A-share market saw a surge in the non-ferrous metals, pharmaceutical biology, and basic chemicals sectors, leading to a wave of stocks hitting the daily limit [1][4] A-share Performance - By the end of the morning session, the Shanghai Composite Index rose by 0.26%, the Shenzhen Component Index by 0.93%, the ChiNext Index by 0.83%, and the Sci-Tech Innovation Index by 1.08% [4] - The non-ferrous metals sector led the gains with an increase of 2.6%, with multiple stocks hitting the daily limit, including Shenzhen New Star, Haixing Co., Rongjie Co., Yunnan Zhiye, and others [4][5] Pharmaceutical Sector - The pharmaceutical biology sector also performed well, with stocks like Hotgen Biotech, Yinuo Si, Shutaishen, and Huana Pharmaceutical seeing increases of over 10% [6][7] - Notable stocks in this sector included Hotgen Biotech with a rise of 14.70% and Shutaishen with an increase of 11.50% [7] Basic Chemicals Sector - The basic chemicals sector experienced significant gains, with stocks such as Keta Biotech and Shandong Haihua hitting the daily limit [8][9] - Keta Biotech saw a remarkable increase of 19.99%, while other stocks in the sector also posted gains around 10% [9] New Listings - A new stock, Puan Medical, was listed today, with its price surging over 170% at one point during the session [11][12] - Puan Medical specializes in diabetes care and related medical devices, with a projected increase in global insulin pen needle sales from 8.81 billion units in 2022 to 9.97 billion units by 2024 [12] Hong Kong Market - The Hong Kong market experienced narrow fluctuations, with China Longgong's stock surging over 20% during the morning session [13][15] - China Longgong reported a total revenue of RMB 11.215 billion for the year 2025, reflecting a year-on-year growth of 9.81%, with significant contributions from electric loaders and export products [15][16]

| 姓名 | 离任职务 | 离任时间 | | | 原定任期到 | | | 离任原因 | 是否继续在 上市公司及 | 是否存在未 履行完毕的 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | | 期日 | | | | 其控股子公 司任职 | 公开承诺 | | 刘葱 | 董事会秘书 | 2026 3 | 年 | 月 | 2027 1 | 年 | 月 | 个人原因 | 否 | 否 | | | | 20 | 日 | | 16 | 日 | | | | | 二、离任对公司的影响 证券代码：603387 证券简称：基蛋生物 公告编号：2026-002 基蛋生物科技股份有限公司 关于董事会秘书辞职的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重 大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 基蛋生物科技股份有限公司（下称"公司"）董事会于近日收到公司董事会秘书刘 葱女士递交的书面辞职报告。因个人原因，刘葱女士申请辞去公司董事会秘书职务。刘 葱女士的辞职报告自 ...

敬请广大投资者理性投资，注意投资风险。 一、股票交易异常波动的具体情况 证券代码：603387 证券简称：基蛋生物 公告编号：2026-001 基蛋生物科技股份有限公司 关于股票交易异常波动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司股票交易连续 3 个交易日内日收盘价格涨幅偏离值累计达到 20%。 经公司自查并向控股股东、实际控制人核实，截至本公告披露日，确认 不存在应披露而未披露的重大事项或重要信息。 基蛋生物科技股份有限公司（以下简称"公司"或"本公司"）股票于 2026 年 3 月 16 日、2026 年 3 月 17 日、2026 年 3 月 18 日连续 3 个交易日内日收盘价 格涨幅偏离值累计达 20%，根据《上海证券交易所交易规则》的规定，属于股票 交易价格异常波动的情况。 二、公司关注并核实的相关情况 经公司自查，公司未发现存在对公司股票交易价格可能产生重大影响的媒体 报道或市场传闻，也未涉及市场热点概念事项。 （四）其他股价敏感信息 经核查，公司未发现其他可能对公司股价产生较 ...

Investment Rating - The report maintains an "Overweight" rating for the in vitro diagnostics (IVD) industry [7]. Core Views - The recent policy from the National Healthcare Security Administration aims to transform the role of healthcare insurance from a payer to an innovator, significantly impacting the IVD industry by promoting solutions that integrate "testing + AI + services" [5][51]. - The domestic IVD industry is currently in a bottoming phase, with a strong focus on the growth potential of immunodiagnostics, particularly in chemiluminescence and molecular diagnostics such as PCR [5][51]. - The report highlights that the biochemical diagnostics sector in China has largely completed its localization process, reducing reliance on foreign technologies [5]. Summary by Sections Industry Performance - The pharmaceutical and biological sector rose by 0.14%, ranking 15th among 31 primary industries, while the IVD sector fell by 1.28% [2][10]. - The IVD sector's current PE (ttm) is 39.37X, with a PB (lf) of 1.80X, showing a slight decrease from the previous week [4][31]. Company Performance - Notable performers in the medical services sector include SAIKOSHI (+14.5%), Ruiang Gene (+3.1%), and Rendu Bio (+2.6%), while underperformers include Cap Bio (-6.8%) and Hotgen Bio (-6.4%) [3][26]. - The report suggests focusing on companies like YHLO Biotech and Shengxiang Bio in the immunodiagnostics and molecular diagnostics fields due to their growth potential [5][51]. Market Trends - The report indicates that the IVD industry is experiencing a shift towards integrating new technologies and payment methods, driven by recent policy changes [5][51]. - The overall IVD market is expected to continue its steady growth, with significant opportunities arising from the integration of AI and innovative products [5][51].

Core Viewpoint - The Nanjing Market Supervision Administration organized a training session to enhance the intellectual property protection capabilities of local medical device companies as they expand into international markets [1][2] Group 1: Training Session Details - The training involved over 20 representatives from listed and key export medical device companies, as well as personnel from intellectual property law firms and service organizations [1] - The format included on-site observation, specialized lectures, and interactive Q&A sessions to help companies identify key issues in overseas intellectual property protection [1] - Experts provided insights on constructing overseas trademark brand strategies and patent risk prevention for medical device companies [1] Group 2: Expert Contributions - Experts Cao Yingjie and Zhang Rui discussed strategies and methods for foreign intellectual property protection during the specialized training sessions [1] - The Q&A segment addressed specific concerns from company representatives regarding trademark and patent layout, international market expansion, and infringement dispute responses [1] Group 3: Future Initiatives - The Nanjing Market Supervision Administration plans to continue optimizing training formats and content to support the innovative and international development of the medical device industry [2]

Core Viewpoint - The company,基蛋生物, is actively expanding its presence in the EU market, which, while currently a small portion of overall revenue, holds significant potential for future growth [1] Group 1: Business Strategy - The EU region contributes a minor share to the company's total revenue but is a crucial part of its international business strategy [1] - The company is enhancing its EU market development through a network of distributors, on-site customer visits, and participation in international exhibitions [1] - Future efforts will focus on advancing a global development strategy, exploring more efficient market expansion and business collaboration models while solidifying existing partnerships [1]

Group 1 - Haitai Xinguang, based in Qingdao, specializes in the research, production, and sales of medical endoscope instruments and optical products, being a leading enterprise in the domestic medical endoscope optical field [1][30] - The company has established long-term collaborations with international medical giants such as Karl Storz and Olympus, and its high-definition optical imaging technology supports navigation equipment for neurosurgery [1][30] - By 2026, the market demand for its high-end optical components is expected to further release due to the recovery of the medical device sector and the advancement of brain-computer interface medical applications [1][30] Group 2 - Huqiang Technology, registered in Yichang, focuses on special protective equipment, pharmaceutical packaging, and medical devices, with a strong advantage in public health emergency material supply [2][31] - Its medical protective equipment is applicable in sterile operating environments for brain-computer interface implantation surgeries, enhancing product competitiveness in the medical device sector [2][31] Group 3 - Zhengde Medical, headquartered in Shaoxing, is a leading enterprise in the medical dressing industry, with a product matrix covering medical dressings, infection control, and rehabilitation care [3][32] - The company's surgical infection control products meet the sterile operation requirements for brain-computer interface implantation surgeries, and its rehabilitation products cater to post-operative patient management needs [3][32] - By 2026, the surgical infection control consumables business is expected to see market growth as brain-computer interface medical applications accelerate [3][32] Group 4 - Linuo Pharmaceutical Packaging, based in Jinan, specializes in the research, production, and sales of pharmaceutical packaging materials, including sterile medical device packaging suitable for brain-computer interface components [4][33] - The company is gradually expanding into the high-end medical device packaging market, seizing opportunities in the brain-computer interface industry [4][33] Group 5 - Rendu Biotech, located in Shanghai, focuses on RNA molecular diagnostic technology, with applications in infection detection post-brain-computer interface implantation surgeries [5][34] - The company’s post-operative infection detection reagents are expected to see new demand growth by 2026 as brain-computer interface clinical surgeries are promoted [5][34] Group 6 - Huangshan Capsule, based in Anhui, specializes in the research and production of pharmaceutical hollow capsules, gradually expanding into medical device auxiliary materials [6][36] - The company’s medical capsule carriers can adapt to the encapsulation needs of sustained-release bioelectrodes in brain-computer interface devices [6][36] Group 7 - ST Kelly, headquartered in Suzhou, focuses on medical device research and production, particularly in ultrasound equipment and rehabilitation devices [7][37] - The company’s ultrasound diagnostic equipment can be used for pre-operative brain tissue imaging assessments in brain-computer interface surgeries [7][37] Group 8 - Aotai Biotech, based in Hangzhou, specializes in rapid diagnostic reagents, with its rapid infection detection reagents applicable in brain-computer interface clinical settings [8][38] - The company is developing rapid detection products for post-operative neurological function assessment related to brain-computer interfaces [8][38] Group 9 - Dongfang Ocean, located in Yantai, focuses on marine biological medical materials, with collagen materials applicable as coatings for brain-computer interface electrodes [9][39] - The company is increasing its R&D investment in the medical device sector, particularly in the integration of biological medical materials with brain-computer interface devices by 2026 [9][39] Group 10 - Shuoshi Biotech, based in Taizhou, specializes in nucleic acid detection technology, with products applicable for precise diagnosis of post-operative brain infections in brain-computer interface surgeries [10][40] - The company is exploring detection technologies related to neurotransmitters in brain-computer interfaces, aiming for breakthroughs in neurological disease diagnostics [10][40] Group 11 - Guofa Co., located in Beihai, focuses on pharmaceutical manufacturing and medical device sales, with a distribution network covering Guangxi and surrounding areas [11][41] - The company plans to increase its agency layout for high-end medical devices related to brain-computer interfaces by 2026 [11][41] Group 12 - Nanwei Co., based in Nantong, specializes in medical dressings and hygiene products, with its adhesive dressings suitable for post-operative care in brain-computer interface surgeries [12][42] - The company is enhancing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [12][42] Group 13 - Mingde Biotech, located in Wuhan, is a leading enterprise in the field of rapid diagnostic reagents, with products applicable for monitoring vital signs during brain-computer interface surgeries [13][43] - The company is developing rapid assessment devices for post-operative neurological function related to brain-computer interfaces [13][43] Group 14 - Hualan Co., based in Wuxi, specializes in medical rubber products, with its rubber sealing components applicable in fluid control systems for brain-computer interface devices [14][44] - The company is collaborating with research institutions to develop rubber insulation components for brain-computer interface electrodes [14][44] Group 15 - Yuyue Medical, headquartered in Danyang, is a leading enterprise in home medical devices, with products applicable in brain-computer interface surgeries [15][45] - The company is increasing its R&D on medical-grade rehabilitation robots, aiming to integrate brain-computer interface technology with rehabilitation devices [15][45] Group 16 - Shengxiang Biotech, located in Changsha, focuses on nucleic acid detection technology, with products applicable for rapid diagnosis of central nervous system infections post-brain-computer interface surgeries [16][46] - The company is exploring gene detection technologies related to neurological genetic diseases, expanding the application boundaries of molecular diagnostics [16][46] Group 17 - Jiga Development, based in Jinan, focuses on high-end medical device incubation and industrialization, particularly in brain-computer interface-related medical device enterprises [17][47] - The company is responsible for industrial park construction and resource integration for brain-computer interface medical device companies [17][47] Group 18 - Anxu Biotech, located in Hangzhou, specializes in rapid diagnostic reagents, with products applicable for instant infection screening during brain-computer interface surgeries [18][48] - The company is developing rapid detection products for neurotransmitters related to brain-computer interfaces, aiming for breakthroughs in neurological function assessment [18][48] Group 19 - Wantai Biotech, based in Beijing, is a comprehensive enterprise in biopharmaceuticals and medical devices, with products applicable for biochemical index detection post-brain-computer interface surgeries [19][49] - The company is exploring biopharmaceutical development related to brain-computer interfaces, seeking new growth points in nerve repair [19][49] Group 20 - Jiuan Medical, located in Tianjin, focuses on home health devices, with products applicable for synchronized monitoring of brain signals and vital signs in brain-computer interface scenarios [20][50] - The company is increasing its R&D investment in brain-computer interface wearable devices, aiming to create an intelligent medical ecosystem [20][50] Group 21 - Jidan Biotech, based in Nanjing, specializes in POCT reagents and instruments, with products applicable for cardiovascular function assessment in brain-computer interface surgeries [21][51] - The company is developing rapid detection products for post-operative cerebrovascular diseases related to brain-computer interfaces [21][51] Group 22 - Wanfeng Biotech, located in Guangzhou, is a leading enterprise in the POCT field, with products applicable for instant infection screening during brain-computer interface surgeries [22][52] - The company is developing neurobiomarker detection reagents to assess post-operative neurological function recovery, providing comprehensive support for brain-computer interface surgeries [22][52] Group 23 - Haier Biotech, based in Qingdao, specializes in low-temperature storage devices for biological materials, with applications in brain-computer interface-related biological sample preservation [23][53] - The company is increasing its R&D on high-end medical storage devices tailored for brain-computer interface biological materials by 2026 [23][53] Group 24 - Haooubo, located in Suzhou, focuses on immune diagnostic reagents and instruments, with products applicable for immune function assessment in brain-computer interface surgeries [24][54] - The company is developing detection reagents for immune rejection post-brain-computer interface implantation, providing technical support for surgical complications [24][54] Group 25 - Shandong Pharmaceutical Glass, based in Zibo, is a leading enterprise in pharmaceutical glass, with products applicable for insulation packaging of brain-computer interface electrodes [25][55] - The company is expanding into the high-end medical device glass materials market, targeting the brain-computer interface industry [25][55] Group 26 - Innotech, located in Langfang, specializes in infectious disease diagnostic reagents, with products applicable for pre-operative lung infection screening in brain-computer interface surgeries [26][56] - The company is developing rapid detection products for post-operative lung infections related to brain-computer interfaces, aiming for breakthroughs in post-operative complication detection [26][56] Group 27 - Jianer Kang, based in Changzhou, focuses on medical dressings and rehabilitation care products, with its antibacterial medical dressings applicable for post-operative care in brain-computer interface surgeries [27][59] - The company is increasing its R&D on functional medical dressings, launching products tailored for long-term post-operative care in brain-computer interfaces [27][59]

Core Viewpoint - The financial performance of 基蛋生物 (Jidan Bio) shows a decline in revenue and net profit for the first nine months of 2025, indicating potential challenges in the company's growth trajectory [2]. Group 1: Financial Performance - For the period from January to September 2025, 基蛋生物 reported a revenue of 758 million yuan, representing a year-on-year decrease of 13.88% [2]. - The net profit attributable to shareholders for the same period was 161 million yuan, down 8.48% year-on-year [2]. - Cumulative cash dividends since the company's A-share listing amount to 847 million yuan, with 391 million yuan distributed over the past three years [2]. Group 2: Shareholder and Market Activity - As of September 30, 2025, the number of shareholders for 基蛋生物 was 25,200, a decrease of 4.22% from the previous period [2]. - The average number of circulating shares per shareholder increased by 4.40% to 20,137 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 12.87 million shares, an increase of 7.10 million shares from the previous period [2]. Group 3: Financing and Trading Activity - On December 26, 基蛋生物's stock price increased by 0.60%, with a trading volume of 48.46 million yuan [1]. - The financing buy amount for the day was 5.66 million yuan, while the financing repayment was 8.06 million yuan, resulting in a net financing outflow of 2.41 million yuan [1]. - The total balance of margin trading for 基蛋生物 as of December 26 was 200 million yuan, with the financing balance accounting for 4.72% of the circulating market value [1].

Market Overview - A and H shares continued to be negatively impacted by the Federal Reserve's lower-than-expected interest rate cuts, with significant declines in sectors such as non-ferrous metals and chemicals [1] - The A-share market saw the Shanghai Composite Index down 3.90%, Shenzhen Component Index down 5.13%, and ChiNext Index down 6.15% [3] - Defensive sectors like banking, media, food and beverage, and defense showed relative resilience, while sectors like power equipment, basic chemicals, and steel experienced significant declines [1][3] Industry Dynamics - The pharmaceutical industry index fell 6.88%, with sub-sectors like chemical pharmaceuticals and bioproducts declining by 7.02% and 7.46% respectively [5] - Eli Lilly became the first global healthcare company to reach a market capitalization of $1 trillion, driven by its GLP-1 weight loss drug contributing 55% of its revenue [7] - Moderna announced the termination of three mRNA projects and secured a $15 billion loan, focusing future efforts on oncology and rare diseases [7] - Innovative drug companies like BeiGene and Innovent Biologics reported significant revenue growth, with BeiGene's global revenue reaching $1 billion, up 51% year-on-year [8] Technology Sector - The technology sector faced significant adjustments, with the Hang Seng Technology Index dropping 7.18% [10] - Nvidia reported Q3 revenue of $57 billion, exceeding expectations, with data center revenue of $51.2 billion, up 66% year-on-year [17] - Google launched the Gemini 3 model, achieving breakthroughs in multi-modal understanding and reasoning capabilities, surpassing competitors [12] - Alibaba's AI application "Qianwen" quickly rose to the fourth position in the App Store rankings, aiming to become a personal AI assistant [13] Investment Strategies - Investment strategies are focusing on technological transformation and de-globalization, with an emphasis on AI and innovative pharmaceuticals [3] - The market is expected to enter a bottoming phase after two weeks of significant adjustments, with a long-term view of a structural bull market [1][3] - The focus is on identifying undervalued technology players within the overseas supply chain [2]